Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $117.7 million versus the consensus estimate of $109.6 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.